Study | Country | Design | Participants | Use of heparin flushing | Antibiotic prophylaxis | Ultrasound guidance | Matching criteriaa | Follow-upb, IJV/SCV | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age, yr (median/mean) | Range | TIVAD | IJV | SCV | ||||||||
Araujoc [15], 2008 | Portugal | PC | 55.5 (median) | 15–83 | Mini-sitimplant | 512 | 551 | Y | N | N | 1,2,3,4,5 | 244/363d (median) |
Biffi [16], 2009 | Italy | RCT | 51.9 (mean) | 18–75 | Bard Port | 117 | 123 | Y | NR | Only for SCV | 1,2,4,6,7,8 | 384/360d (median) |
Plumhans [31], 2011 | Germany | PC | 56 (mean) | 18–85 | Bard Port | 44 | 94 | Y | NR | Only for IJV | 7,8 | 6 mo (mean) |
Aribaş [38], 2012 | Turkey | RC | 53.8 (mean) | 16–84 | Polysite | 248 | 99 | Y | NR | Y | 1,2,4,7,8 | 219.5d (mean) |
Ribeiro [39], 2012 | Brazil | RCT | < 18Â yr | NR | NR | 34 | 43 | Y | Y | N | 1,2,4,6,7,8 | 14.8/12.6 mo (mean) |
Vetter [21], 2013 | Germany | RC | 53 (mean) | 2–84 | INTRAPORT | 71 | 32 | Y | Y | N | 1,2 | 451d (mean) |
Liud [40], 2014 | China | RC | 45.4 (mean) | 8–86 | Bardport | 222 | 398 | Y | NR | N | 1,2,3,4 | 1079.3/995.2d (mean) |
Miao [41], 2014 | China | RCT | 58.1 (mean) | 25–81 | NR | 107 | 107 | Y | Y | Only for IJV | 1,2,3,4,8 | 215/209d (mean) |
Nagasawae [17], 2014 | Japan | RC | 64 (median) | 25–85 | BARD X-port isp | 136 | 97 | NR | NR | Only for IJV | 3 | 566/402d (mean) |
Ozbudak [42], 2014 | Turkey | RC | 56.38 (mean) | 14–83 | FB Medical/Districlass medical SA | 178 | 224 | Y | N | Y for some patients | 3,8 | 507d (median) |
Wu [18], 2014 | Taiwan | RC | 57.7 (mean) | 0.5–94 | Arrow/Bard/ Tyco | 63 | 234 | Y | NR | N | NA | 4.5 yr (mean) |
Jung [23], 2015 | Korea | RC | 59 (median) | 1–82 | Bard Port | 92 | 79 | NR | NR | N | 1,2,4,7 | 278d (median) |